Attachment of Cell-Binding Ligands to Arginine-Rich Cell-Penetrating Peptides Enables Cytosolic Translocation of Complexed siRNA

Component: CPP Core; Description: Nona-arginine (9R) — homopolymeric arginine CPP; tested as L-isoform (9LR) and D-isoform (9DR) (protease-resistant)

Component: Targeting Ligands; Description: • RVG (29-mer peptide from Rabies virus glycoprotein) — binds nicotinic acetylcholine receptor (nAchR) subunits; targets Neuro2a cells<br>• scFvCD7 (single-chain antibody) — binds CD7 on human T cells; targets Jurkat cells

Component: Ligand-9R Chimeras; Description: RVG-9DR, RVG-9LR, scFvCD7-9DR, scFvCD7-9LR

Component: siRNA Payload; Description: • siGFP (targets GFP reporter)<br>• siSOD1 (targets murine SOD-1)<br>• siCD4 (targets human CD4)<br>• siLuc (control, targets firefly luciferase)<br>• FITC- or Cy5-labeled siLuc (fluorescent tracking)

Component: Complex Formation; Description: Electrostatic complexation at peptide:siRNA ratios 10:1 (unless otherwise noted); final peptide concentration 1-5 μM

Component: Nanoparticle Properties; Description: • 9R:siRNA complexes: nanoparticle formation at ≥10:1 molar ratios<br>• RVG-9R:siRNA: similar binding and nanoparticle formation<br>• Ligand attachment lowers zeta potential, suggesting weaker association

Component: Key Controls; Description: Native 9DR/LR (no ligand), Lipofectamine 2000, siRNA alone, RVG without 9R, α-bungarotoxin (nAchR inhibitor)

Parameter: Cell Lines; Details: • Neuro2a (mouse neuroblastoma) — expresses nAchR; stably expressing GFP for silencing assays<br>• Jurkat (human T cell line) — CD7⁺; resistant to conventional transfection

Parameter: Transfection Conditions; Details: 100 pmol siRNA (Neuro2a) or 200 pmol siRNA (Jurkat); 10:1 carrier:siRNA ratio; 1-5 μM final peptide concentration; serum-free DMEM/RPMI for complex formation

Parameter: Transfection Duration; Details: 20 min complexation at RT; added to cells; medium refreshed after 1 h for experiments >1 h

Parameter: Pharmacological Inhibitors; Details: • Cytochalasin D (5 μM) — actin polymerization inhibitor<br>• Dynasore (80 μM) — dynamin inhibitor<br>• E-64d (40 μM) — membrane-permeable cysteine protease inhibitor (endosomal proteolysis)<br>• α-Bungarotoxin (10⁻⁵ M) — competitive nAchR inhibitor (blocks RVG binding)

Parameter: Genetic Manipulations; Details: • Wild-type and dominant-negative (S34N, T22N) Rab5-GFP and Rab7-GFP (block early/late endosome maturation)<br>• α6-mCherry, α4, β2 nAchR subunits (receptor aggregation studies)

Parameter: Replicates; Details: Three independent experiments; data shown as mean ± SEM or ± SD

Parameter: Statistical Tests; Details: One-way ANOVA with Bonferroni's multiple-comparison test; two-tailed t-test

Analysis Category: CPP/SiRNA Uptake; Methods: Flow cytometry (BD FACS Calibur): MFI and % positive cells for FITC/Cy5-labeled siRNA

Analysis Category: Gene Silencing; Methods: • Flow cytometry: % GFP-negative cells (Neuro2a-GFP)<br>• qPCR (SYBR Fast, 7500 Fast Real-Time PCR): murine SOD-1 (normalized to GAPDH), human CD4 (normalized to β-actin)

Analysis Category: Live-Cell Imaging; Methods: • Spinning disc Nikon TE2000 confocal with environmental chamber (37°C, 5% CO₂)<br>• Leica TCS SP5 Spectral Confocal (63×)<br>• LysoTracker Red (late endosomes), Hoechst 33342 (nuclei)

Analysis Category: Membrane Inversion; Methods: Alexa568-labeled annexin V (stains exposed phosphatidylserine); live confocal imaging and flow cytometry

Analysis Category: Particle Characterization; Methods: Dynamic light scattering (Malvern Zetasizer Nano ZS): Z-average size and zeta potential

Analysis Category: siRNA Stability; Methods: • RNase A protection assay (100 ng, 37°C)<br>• Serum protection assay (50% human AB serum)<br>• Proteinase K treatment followed by phenol-chloroform RNA extraction; agarose gel electrophoresis

Analysis Category: pH-Dependent Binding; Methods: Ethidium bromide exclusion assay (pH 5.0-7.0); fluorescence measurement (ex: 531 nm, em: 590 nm)

Analysis Category: Image Analysis; Methods: Volocity 6.2.1 software; Image J 1.49b for intensity quantification; Velocity software for cytoplasmic vs. vesicular fluorescence distribution

Formulation: 9DR:siRNA; Cell Type: Neuro2a; Uptake (MFI, 24 h): 6.7 ± 0.2; Gene Silencing: No GFP silencing

Formulation: 9LR:siRNA; Cell Type: Neuro2a; Uptake (MFI, 24 h): 11.2 ± 1.4; Gene Silencing: No GFP silencing

Formulation: RVG-9DR:siRNA; Cell Type: Neuro2a; Uptake (MFI, 24 h): 627 ± 124; Gene Silencing: GFP-negative cells: 42.1%

Formulation: RVG-9LR:siRNA; Cell Type: Neuro2a; Uptake (MFI, 24 h): 1,527 ± 121; Gene Silencing: GFP-negative cells: 69.8%

Formulation: Lipofectamine 2000; Cell Type: Neuro2a; Uptake (MFI, 24 h): 81 ± 0.66; Gene Silencing: GFP-negative cells: 46.6%

Formulation: scFvCD7-9DR:siRNA; Cell Type: Jurkat; Uptake (MFI, 24 h): 70.83 ± 26.05; Gene Silencing: CD4 knockdown: 64.5% at 4 h

Formulation: scFvCD7-9LR:siRNA; Cell Type: Jurkat; Uptake (MFI, 24 h): 104.6 ± 12.27; Gene Silencing: CD4 knockdown: 65.6% at 4 h

Formulation: 9DR/LR:siRNA; Cell Type: Jurkat; Uptake (MFI, 24 h): ~20 (no enhancement); Gene Silencing: No knockdown

Parameter: Time to cytoplasmic fluorescence; RVG-9DR: 26.4 ± 2.7 min; RVG-9LR: 22.1 ± 2.8 min

Parameter: Actin/dynamin dependence; RVG-9DR: Independent (cytochalasin D/dynasore no effect); RVG-9LR: Independent

Parameter: Early endosome colocalization (1 h); RVG-9DR: Some EEA1⁺; RVG-9LR: Some EEA1⁺

Parameter: Late endosome colocalization (1 h); RVG-9DR: None (LysoTracker⁻); RVG-9LR: None (LysoTracker⁻)

Parameter: mRNA knockdown (1 h, SOD-1); RVG-9DR: Significant; RVG-9LR: Significant

Condition: RVG-9LR:siRNA; Annexin V Positivity: Strong, localized to ligand-binding sites (within 30 min; persists to 2 h)

Condition: RVG-9DR:siRNA; Annexin V Positivity: Strong, localized (comparable)

Condition: RVG-9LR alone (no siRNA); Annexin V Positivity: Moderate (less than with siRNA)

Condition: 9LR:siRNA (no ligand); Annexin V Positivity: None

Condition: RVG alone (no 9R):siRNA; Annexin V Positivity: None

Condition: RVG-9LR:siRNA + α-bungarotoxin; Annexin V Positivity: None (receptor binding required)

Condition: 24 h post-transfection; Annexin V Positivity: Annexin V negative, siRNA still positive

Parameter: Cytoplasmic siRNA; RVG-9DR:siRNA (24 h): <10% of cells; RVG-9LR:siRNA (24 h): ~40% of cells

Parameter: Late endosome localization; RVG-9DR:siRNA (24 h): Dominant (LysoTracker⁺); RVG-9LR:siRNA (24 h): Reduced

Parameter: Rab7 dominant-negative block; RVG-9DR:siRNA (24 h): Minimal effect; RVG-9LR:siRNA (24 h): Almost complete accumulation in vesicles

Parameter: Rab5 dominant-negative block; RVG-9DR:siRNA (24 h): Minimal effect; RVG-9LR:siRNA (24 h): Almost complete accumulation in vesicles

Parameter: E-64d (protease inhibitor) effect; RVG-9DR:siRNA (24 h): Minimal; RVG-9LR:siRNA (24 h): Dramatic vesicle accumulation, reduced cytoplasmic fluorescence

Time: 4 h; RVG-9DR:siSOD1: Significant knockdown; RVG-9LR:siSOD1: Significant knockdown

Time: 24 h; RVG-9DR:siSOD1: Significant knockdown; RVG-9LR:siSOD1: Higher knockdown

Time: 36 h; RVG-9DR:siSOD1: Knockdown lost (mRNA re-accumulates); RVG-9LR:siSOD1: Significant knockdown persists

Time: 96 h; RVG-9DR:siSOD1: Effects ceased; RVG-9LR:siSOD1: Effects ceased (cell doubling)

Assay: RNase A protection (3 h, serum-free); RVG-9DR:siRNA: Intact; RVG-9LR:siRNA: Intact

Assay: Serum protection (3 h, 50% human serum); RVG-9DR:siRNA: Intact (up to 24 h); RVG-9LR:siRNA: Significant degradation by 3 h

Assay: E-64d effect on silencing (36 h); RVG-9DR:siRNA: Minimal reduction; RVG-9LR:siRNA: Significant reduction (protease-dependent)

Assay: pH-dependent binding (pH 5.0 vs. 7.0); RVG-9DR:siRNA: Complex stable; RVG-9LR:siRNA: Complex tighter at low pH

1. In vitro only: All experiments performed in cultured cell lines (Neuro2a, Jurkat); no in vivo siRNA delivery, biodistribution, or therapeutic efficacy studies.

2. Potential for fluorophore artifacts: The authors note that "fluorophore released by nuclease-degraded siRNA that has dissociated from ligand-9LR due to protease action could have contributed to cytosolic fluorescence." However, prolonged mRNA knockdown validated functional siRNA activity.

3. Mechanism of endosomal release not fully resolved: The authors propose that "late endosome to cytosol is a second, more controlled route that extends the kinetics of gene silencing through proteolytic disruption of ligand9LR:siRNA complexes," but the precise molecular mechanism (membrane flipping, pore formation, or other) remains speculative.

4. Receptor identity unknown: "It is not known which of the nAchR subunits the RVG peptide binds." While α6-mCherry was used as a proxy, the exact receptor engagement remains incompletely characterized.

5. Cell-type specificity of uptake: RVG-9R targets nAchR-expressing cells; scFvCD7 targets CD7⁺ T cells. The approach is receptor-dependent and would not be broadly applicable without a suitable targeting ligand for the cell type of interest.

6. E-64d inhibitor specificity: E-64d inhibits cysteine proteases broadly; the specific endosomal protease(s) responsible for 9LR degradation and siRNA release were not identified.

7. Potential cytotoxicity: The authors state that no LDH release or Alamar blue cytotoxicity was detected despite annexin V positivity; however, detailed cytotoxicity dose-response studies across multiple cell types were not presented.

8. Limited characterization of ligand-9R:siRNA complexes: While DLS data are provided, more detailed characterization (e.g., TEM, stability in serum over time, encapsulation efficiency) is limited.

9. No demonstration with therapeutic siRNA targets: SOD-1 and CD4 are model targets; no demonstration with clinically relevant disease targets (e.g., oncogenes, viral genes) was performed.

10. siRNA delivery to primary cells not shown: While Jurkat cells (suspension, hard-to-transfect) were used, primary human T cells or other primary cells were not evaluated.

11. Ligand-9LR vs. 9DR proteolysis: The authors propose that "some level of degradation of the 9R carrier in the late endosome may be a dominant factor contributing to the overall efficiencies of RNAi achieved by ligand-9LR delivery systems." However, direct evidence of 9LR peptide cleavage in endosomes (e.g., by mass spectrometry of degraded products) was not provided.

Report prepared based on the published Cell Chemical Biology article. For full experimental details, supplementary figures, and videos, please refer to the original publication and accompanying supplemental information.